Bioray Biotech Co

Bioray Biotech Co EBITDA per Share

The EBITDA per Share of Bioray Biotech Co (7561.TWO) as of Oct 16, 2026 is 1.28 TWD. In the previous year, EBITDA per Share was -0.14 TWD — a change of -988.77% (higher).

EBITDA per Share

1.28TWD

YoY

-988.77%

Last updated:

EBITDA per Share of Bioray Biotech Co is 2025 1.28 TWD. EBITDA per Share of Bioray Biotech Co was 2024 -0.14 TWD. It decreases by -988.77% higher compared to the previous year.

The Bioray Biotech Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.57 TWD
Jan 1, 2019
0.25 TWD
Jan 1, 2020
-0.01 TWD
Jan 1, 2021
-0.30 TWD
Jan 1, 2022
-0.01 TWD
Jan 1, 2023
-0.64 TWD
Jan 1, 2024
-0.14 TWD
Jan 1, 2025
1.28 TWD
The Bioray Biotech Co EBITDA per Share history
YEAREBITDA per ShareYoY
1.28TWD-988.77%
-0.14TWD-77.63%
-0.64TWD+7,871.13%
-0.01TWD-97.34%
-0.30TWD+3,642.56%
-0.01TWD-103.24%
0.25TWD-56.29%
0.57TWD-2,968.45%
-0.02TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bioray Biotech Co Stock analysis

What does Bioray Biotech Co do? Bioray Biotech Co Ltd is a company based in Tainan, Taiwan, operating within the Health Care sector, specifically in the Biotechnology industry. The company went public on July 6, 2020, with its ticker listed as 7561.TWO and ISIN TW0007561B13. Bioray Biotech focuses on the development of biological health products, functional medical testing, and cell storage and preparation services. The company's product portfolio includes personalized probiotics, anti-allergic and intestinal probiotics, diabetes probiotics, and female urinary tract health products. In the functional medical testing segment, the company offers services such as personalized bacteria testing, personalized fungi testing, intestinal normal bacteria analysis, quantitative detection of magnesium in red blood cells, polymorphism analysis of metabolic-related genes, and lymphocyte grouping. For cell storage and preparation, Bioray Biotech provides stem cell storage, immune cell storage, and cytokine-induced killer (CIK) immune cell preparations. The company's website is https://bio-ray.com.tw/, where further information about its services and products can be found. Bioray Biotech is engaged in the development and provision of specialized health-related services and products, primarily targeting personalized health solutions through biotechnology. Bioray Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioray Biotech Co stock

EBITDA per Share of Bioray Biotech Co is 1.28 TWD in 2025.

EBITDA per Share of Bioray Biotech Co changed from -0.14 TWD to 1.28 TWD, representing a -988.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Bioray Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Bioray Biotech Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Bioray Biotech Co